TransThera Sciences (Nanjing) Announces Clinical Results of Tinengotinib Published in Nature Communications
Key Highlights
- TransThera Sciences (Nanjing), Inc. has voluntarily announced a significant milestone: the clinical results of its spectrum-selective multi-kinase inhibitor, tinengotinib, have been published in Nature Communications (Impact Factor 15.7).
- The publication covers tinengotinib’s performance as both a monotherapy and in combination with atezolizumab for treating advanced solid tumors.
- The phase Ib/II study (NCT05253053) was conducted in China and evaluated two arms:
- Arm A: Tinengotinib monotherapy (n = 53, patients with advanced solid tumors)
- Arm B: Tinengotinib in combination with atezolizumab (n = 31, patients with advanced biliary tract cancer)
- Efficacy Results:
- Monotherapy ORR: 16.7% in advanced solid tumors
- Combination therapy ORR: 22.6% in advanced biliary tract cancer
- Subgroup analysis in cholangiocarcinoma:
- Monotherapy ORR: 30.8% (n = 13)
- Combination ORR: 25.0% (n = 28)
- FGFR2 fusion cholangiocarcinoma (progressed on prior FGFR inhibitors): Monotherapy ORR: 66.7%
- Patients previously treated with immune checkpoint inhibitors (n = 20): Combination therapy ORR: 20.0%; Disease Control Rate (DCR): 75.0%
- Tinengotinib targets FGFR1-3, JAK1/2, VEGFRs, and Aurora A/B kinases, representing a potential new therapeutic option for difficult-to-treat cancers.
Potentially Price-Sensitive and Shareholder-Relevant Information
- This publication in a high-impact scientific journal signals strong scientific validation and visibility for TransThera’s lead candidate, tinengotinib.
- Positive clinical data, especially for monotherapy in FGFR2 fusion cholangiocarcinoma (with an impressive ORR of 66.7%), may position tinengotinib as a promising new treatment for patients who have exhausted current options.
- The combination therapy’s efficacy in patients who previously received immune checkpoint inhibitors (ORR of 20% and DCR of 75%) opens doors for further clinical development and potential new indications.
- Further development of tinengotinib as monotherapy and in combination with immunotherapy is supported by these findings, possibly affecting future valuation and investor sentiment.
- However, shareholders should note the formal warning under Rule 18A.08(3) of the HKEX Listing Rules: There is no assurance that tinengotinib or related products will ultimately be successfully developed and marketed.
Board and Corporate Information
- Announcement signed by Dr. Frank Wu, Chairman & CEO, on 17 May 2026.
- Current board composition: Dr. Frank Wu and Mr. Wu Di (executive directors), Ms. Jia Zhongxin (non-executive director), Mr. Li Shu Pai, Ms. Chui Hoi Yam, and Ms. Zheng Zhelan (independent non-executive directors).
Implications for Investors
- The publication represents a major scientific milestone and may positively influence investor confidence, pending further successful clinical development and regulatory milestones.
- Investors should monitor future updates regarding clinical progress, regulatory approvals, and commercialization plans for tinengotinib.
- As is common in early-stage biotech, risks remain high until regulatory approval and market entry are achieved.
Disclaimer
The information above is based on the voluntary announcement by TransThera Sciences (Nanjing), Inc. and is intended for informational purposes only. There is no guarantee that tinengotinib or related products will ultimately be successfully developed, approved, or marketed. Investors should exercise caution and seek professional advice before making any investment decisions.
